Aclarion Expands Nociscan Technology with Scripps Health Partnership
BROOMFIELD, Colo., March 03, 2025 (GLOBE NEWSWIRE) – Aclarion, Inc. (Nasdaq: ACON, ACONW), a pioneering healthcare technology company utilizing biomarkers and proprietary AI-driven algorithms to enhance chronic low back pain (cLBP) diagnostics, has announced a commercial agreement with Scripps Health in San Diego, CA. This partnership brings Aclarion’s Nociscan technology to the largest healthcare system in the region, giving Scripps Green and Scripps Health spine physicians access to innovative diagnostic tools for patients suffering from cLBP.
Enhancing Patient Care with Advanced Diagnostics
Each year, Scripps Health evaluates a growing number of patients struggling with chronic low back pain. Dr. Robert Eastlack, an esteemed orthopedic surgeon at Scripps Health, highlighted the impact of this new collaboration:
“I have a strong interest in advanced diagnostics and clinical decision support tools like Nociscan. Over the past few years, I have referred numerous patients to Beverly Hills for Nociscan testing, and the additional insights it provides have proven invaluable. Now, with Nociscan available at Scripps Green, more of my colleagues and patients will benefit from this groundbreaking technology.”
Scripps Health, a nonprofit healthcare system with five hospitals and 19 outpatient facilities, serves over half a million patients annually with the support of 2,600 affiliated physicians. The system is also recognized for its contributions to clinical research and medical education, making it an ideal partner for Aclarion’s innovative solutions.
A Breakthrough in Chronic Low Back Pain Diagnostics
Aclarion’s Nociscan is the first evidence-supported SaaS platform designed to noninvasively distinguish between painful and nonpainful discs in the lumbar spine. By objectively quantifying chemical biomarkers associated with disc pain, Nociscan delivers critical insights that enhance existing diagnostic tools. This advanced approach supports physicians in identifying the precise source of cLBP, leading to more effective treatment plans and improved patient outcomes.
Ryan Bond, Chief Strategy Officer at Aclarion, emphasized the significance of the partnership:
“Dr. Eastlack is a leader in spine research, contributing to over 100 peer-reviewed articles and numerous textbooks. By integrating Nociscan into Scripps Health, we are providing millions of people throughout Southern California with access to cutting-edge spine care solutions.”
Addressing a Global Health Crisis
Chronic low back pain is a significant healthcare challenge, affecting approximately 266 million individuals worldwide due to degenerative spine disease. The integration of Nociscan at Scripps Health marks a crucial step toward improving diagnostics and treatment for patients dealing with this pervasive condition.
With this latest expansion, Aclarion continues to lead the charge in revolutionizing spine care through AI-driven diagnostics, providing physicians with the tools they need to **enhance patient outcomes and advance re
